The other two are small molecules (glibenclamide to treat neonatal diabetes mellitus and setmelanotide to treat obesity associated with biallelic pro-opiomelanocortin (POMC), including PCSK1, deficiency obesity or leptin receptor (LEPR) deficiency obesity). This evidence concerns the gene POMC and obesity disorder.